Table 2.
Differences in IL-10 levels by COPD disease severity after stimulation of whole blood by PAMPs
| PAMP | COPD severity
|
P-value* | |||
|---|---|---|---|---|---|
| FEV1 <50 (N=16)
|
FEV1 50–80 (N=12)
|
||||
| Median | IQR | Median | IQR | ||
| Media | 0.24 | (0.2–0.5) | 0.2 | (0.2–0.2) | 0.6 |
| Pam3Cys (10 ng/mL) | 31.3 | (7.8–108.7) | 52.6 | (20.9–100.3) | 0.6 |
| Pam3Cys (100 ng/mL) | 57.8 | (13.7–160.0) | 84.1 | (54.5–145.0) | 0.5 |
| Zymosan (10 μg/mL) | 5.2 | (2.2–9.2) | 7.4 | (5.8–20.9) | 0.05 |
| Zymosan (100 μg/mL) | 34.9 | (22.6–55.2) | 67.3 | (39.6–104.2) | 0.007 |
| FSL-1 (10 ng/mL) | 9.9 | (1.5–33.3) | 35.1 | (12.4–45.3) | 0.06 |
| FSL-1 (100 ng/mL) | 40.5 | (18.1–98.5) | 80.2 | (46.6–119.1) | 0.08 |
| O111:B4 (0.1 ng/mL) | 1.4 | (0.7–3.0) | 2.1 | (0.8–5.1) | 0.4 |
| O111:B4 (1 ng/mL) | 10.6 | (3.2–21.1) | 16.6 | (12.5–24.0) | 0.2 |
| O111:B4 (10 ng/mL) | 18.2 | (7.0–31.8) | 29.1 | (24.3–45.8) | 0.05 |
| Re595UP (0.01 ng/mL) | 2.7 | (0.2–9.6) | 9.1 | (6.8–12.1) | 0.009 |
| Re595UP (0.1 ng/mL) | 29.0 | (15.2–52.6) | 49.9 | (34.6–74.6) | 0.05 |
| Re595UP (1 ng/mL) | 58.7 | (32.5–83.9) | 79.5 | (57.5–108.0) | 0.2 |
| Flagellin (100 ng/mL) | 0.9 | (0.9–1.3) | 0.9 | (0.9–0.9) | 0.4 |
| R848 (0.1 μM) | 0.6 | (0.2–1.6) | 0.2 | (0.2–0.3) | 0.1 |
| R848 (1 μM) | 347.2 | (168.2–574.3) | 440.1 | (329.3–673.0) | 0.3 |
Note:
*
Wilcoxon rank sum test (Mann–Whitney).
Abbreviations: IL, interleukin; PAMP, pathogen-associated molecular pattern; IQR, inter-quartile range.